Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Zhu, Xiaojian  [Clear All Filters]
2024
Li N, Zhang R, Wang J, Zhu X, Meng F, Cao Y, Wang GX, Yang Y. Case report: Acute HHV6B encephalitis/myelitis post CAR-T cell therapy in patients with relapsed/refractory aggressive B-cell lymphoma. Front Neurol. 2024;15:1334000.
Liu W, Wu J, Ming X, Zhang Q, Zhou D, Zheng R, Zhou M, Shang Z, Chen L, Zhu X, et al. Case report: The utilization of crizotinib and brentuximab vedotin as a bridge to autologous stem cell transplantation and followed by CD30-directed CAR-T cell therapy in relapsed/refractory ALK+ ALCL. Front Immunol. 2024;15:1346001.
Xin X, Zhu X, Yang Y, Wang N, Wang J, Xu J, Wei J, Huang L, Zheng M, Xiao Y, et al. Efficacy of programmed cell death 1 inhibitor maintenance after chimeric antigen receptor T cells in patients with relapsed/refractory B-cell non-Hodgkin-lymphoma. Cell Oncol (Dordr). 2024.
Xin X, Lin L, Yang Y, Wang N, Wang J, Xu J, Wei J, Huang L, Zheng M, Xiao Y, et al. Prognostic differences between carmustine, etoposide, cytarabine and melphalan (BEAM) and carmustine, etoposide, cytarabine, melphalan and fludarabine (BEAMF) regimens before autologous stem cell transplantation plus chimeric antigen receptor T therapy in. Cytotherapy. 2024.
Fu A, Peng Y, Cheng P, Wu J, Zhu X, Yang Y, Huang L, Wang N, Wang J, Xu J, et al. Recombinant Human Thrombopoietin Promotes Platelet Engraftment in Severe Aplastic Anemia Patients following Treatment with Haploid Hematopoietic Stem Cell Transplantation using Modified Post-transplantation Cyclophosphamide. Transplant Cell Ther. 2024.
Zhang Q, Li C, Cao Y, Wang N, Huang L, Shang Z, Wang J, Huang L, Xu J, Xiao M, et al. Upper gastrointestinal tract immune-related adverse events: Two cases of obstructive complications occurred in immune consolidation therapy after sequential chimeric antigen receptor T cell therapy with autologous hematopoietic stem cell transplantation f. Clin Case Rep. 2024;12(1):e8411.
2023
Sun T, Li D, Huang L, Zhu X. Inflammatory abrasion of hematopoietic stem cells: a candidate clue for the post-CAR-T hematotoxicity?. Front Immunol. 2023;14:1141779.
2016
Li Q, Zhong Z, Zeng C, Meng L, Li C, Luo Y, Wang H, Li W, Wang J, Cheng F, et al. A clinical observation of Chinese chronic myelogenous leukemia patients after discontinuation of tyrosine kinase inhibitors. Oncotarget. 2016.